Exclusive

Publication

Byline

राष्ट्रीय साधन सह योग्यता छात्रवृत्ति में बेलारही स्कूल के चार छात्रों का शानदार प्रदर्शन

मधुबनी, अप्रैल 6 -- झंझारपुर। बेलारही स्थित राजकीय उत्क्रमित मध्य विद्यालय के चार प्रतिभाशाली छात्रों ने राष्ट्रीय साधन सह योग्यता छात्रवृत्ति (एनएमएमएस) परीक्षा में उत्कृष्ट प्रदर्शन कर विद्यालय और क... Read More


TMNT Empire City lands April 30 and VR fans are finally getting their Turtle fantasy

India, April 6 -- This part really gets to be fun for many players. How would a TMNT game let you not only choose a turtle but actually make you feel like one? That is what Empire City is all about. W... Read More


गर्मी में विद्युत व्यवस्था बनाये रखने पर किया मंथन

अयोध्या, अप्रैल 6 -- अयोध्या। गर्मी में शहर और जनपद के ग्रामीण क्षेत्रों में विद्युत आपूर्ति व्यवस्थ बनाये रखने और खराबियों को दूर करने को लेकर विभागीय स्तर पर मंथन चल रहा है। सोमवार को अधीक्षण अभियंत... Read More


China's Communist Party investigates ex-Xinjiang leader Ma Xingrui

New Delhi, April 6 -- The disciplinary body for China 's Communist Party said Friday it has placed the former Xinjiang party chief under investigation over suspected violations of discipline and law. ... Read More


Singapore Clinical Trial: 'Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the post-operative survival of glaucoma drainage devices'

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the po... Read More


Singapore Clinical Trial: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy.

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507... Read More


Singapore Clinical Trial: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemothera... Read More


Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safet... Read More


Singapore Clinical Trial: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) M... Read More


Singapore Clinical Trial: DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig i... Read More